Maintaining and Improving Access to PAH Care

Addressing the Social Determinants of Health and Decreasing Disparities in PAH: A Focus on Technology, Practice-Changing Tools and Advancing Therapies


Vallerie V. McLaughlin, MD

Faculty Chair

Professor of Medicine

Director, Pulmonary Hypertension Program

University of Michigan Medical School

Ann Arbor, MI

Jean M. Elwing, MD


Professor of Medicine

Division of Pulmonary, Critical Care and Sleep Medicine

University of Cincinnati

Cincinnati, OH

Nicholas Kolaitis, MD, MAS


Assistant Professor

Pulmonary, Critical Care, Allergy and Sleep Medicine

University of California at San Francisco

San Francisco, CA

R. James White III, MD, PhD


Professor of Medicine, Pharmacology, and Physiology

School of Medicine and Dentistry

University of Rochester Medical Center

Rochester, NY

Program Overview

Many PAH patients remain undiscovered, undiagnosed, and underserved. The reasons for this are vast but central to the treatment of these patients is a need to make PAH care more accessible. The COVID-19 pandemic has further exacerbated the need to connect with not only with undiagnosed PAH patients, but even those currently under care. Part of the solution to these modern-day issues centers on reducing medical and ancillary costs to patients and making the most of telemedicine.

Through the lens of SDoH, we explore the rising prevalence of Methamphetamine-associated Pulmonary Arterial Hypertension (Meth-APAH) and the unique and unmet needs of patients and uncover how this phenotype differs in its characteristics and outcomes from idiopathic PAH.

Key themes brought to light in the program include the burdens many patients and healthcare providers face including financial costs of care and the prejudices many experience or perceive.

Target Audience

This educational initiative is designed for cardiologists, pulmonologists, critical care clinicians and primary care practitioners, including advanced practice clinicians (nurse practitioners and physician assistants) nurses and pharmacists.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Explain how to implement newly refined risk assessment tools, standard of care therapy and new clinical trial data into practice where appropriate
  • Recognize the nonspecific symptoms of PAH as well as the social determinants of health (SDoH) that can impact treatment outcomes to better manage all patients with PAH, including those who historically have been underserved
  • Describe the clinical presentation and outcomes of methamphetamine-associated PAH compared with those of idiopathic PAH and how SDoH can impact patient outcomes


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium Continuing Education (Iridium). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must
  • Read the learning objectives and faculty disclosures Complete the pretest
  • View the broadcast
  • Complete the posttest with a score of 70% or higher

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected]


Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Vallerie V. McLaughlin, MD (Chair)
Consulting Fee (e.g., Advisory Board): Aerami, Aerovate, Altavant, Bayer, Caremark LLC, Corvista, Gossamer Bio, Janssen, Merck, United Therapeutics
Contracted Research: Aerovate, Altavant, Gossamer Bio, Janssen, Merck, Sonovie

Jean M. Elwing MD
Consulting Fee (e.g., Advisory Board): Acceleron/Merck, Aerovate, Altavant, Bayer, Gossamer Bio, Liquida, Janssen, Insmed, United Therapeutics
Contracted Research: Acceleron/Merck, Aerovate, Altavant, Bayer, Janssen, Liquidia, Gossamer Bio, Pharmosa, Phase Bio, Tenax, United Therapeutics

Nicholas Kolaitis, MD, MAS
Consulting Fee (e.g., Advisory Board): Accleron, Janssen, United Therapeutics

R. James White III, MD, PhD
Consulting Fee (e.g., Advisory Board): Altavant, Bayer, Merck
Contracted Research: Altavant, Bayer, Gossamer Bio, Merck, United Therapeutics

The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by Global Education Group and Iridium Continuing Education.
This educational activity is supported by educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson and Merck Sharp & Dohme LLC.

Credit Amount: 0.50
Credit Type: AMA
Release: March 21, 2023
Expiration: March 21, 2024